Cancer therapy with trifunctional antibodies: Linking innate and adaptive immunity

Future Oncology

Volumn 8, Issue 1, 2012, Pages 73-85

  Hess, Juergen ^a   Ruf, Peter ^b   Lindhofer, Horst ^a,b  

^a TRION Pharma GmbH   (Germany)

^b TRION Research GmbH   (Germany)

Author keywords

bispecific antibodies; catumaxomab; CD3; cytotoxic T cells; humoral immunity; Removab ; trifunctional antibodies; Triomab ; tumor associated antigens; vaccination

Indexed keywords

CATUMAXOMAB; CD3 ANTIBODY; ERTUMAXOMAB; FC RECEPTOR; IMMUNOGLOBULIN G; RITUXIMAB; TRASTUZUMAB;

ACCESSORY CELL; ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASCITES TUMOR; BREAST CANCER; BREAST METASTASIS; CANCER IMMUNIZATION; CANCER PATIENT; CANCER THERAPY; CARCINOMATOUS PERITONITIS; CELL ACTIVATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; T LYMPHOCYTE; TH1 CELL; TREATMENT OUTCOME; TUMOR MODEL;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; BIOPHARMACEUTICS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, INNATE; NEOPLASMS; T-LYMPHOCYTES;

EID: 83655203270     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.138     Document Type: Review

References (78)

1. Jacobs N, Mazzoni A, Mezzanzanica D et al. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation. Cancer Immunol. Immunother. 44, 257-264 (1997). (Pubitemid 27306903)
2. Zeidler R, Mysliwietz J, Csanady M et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells, and induces direct phagocytosis of tumour cells. Br. J. Cancer 83, 261-266 (2000). (Pubitemid 30411727)
3. Riechelmann H, Wiesneth M, Schauwecker P et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol. Immunother. 56, 397-1406 (2007).
4. Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schroder P, Lindhofer H. Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B cell lymphoma cells even with very low CD20 expression levels. Int. J. Cancer 123, 1181-1189 (2008).
5. Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J. Histochem. Cytochem. 49, 911-917 (2001). (Pubitemid 32565984)
6. Ruf P, Jager M, Ellwart J, Wosch S, Kusterer E, Lindhofer H. Two new trifunctional antibodies for the therapy of human malignant melanoma. Int. J. Cancer 108, 725-732 (2004). (Pubitemid 38076404)
7. Zeidler R, Reisbach G, Wollenberg B et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol. 163, 1246-1252 (1999). (Pubitemid 29352740)
8. Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res. 69, 4270-4276 (2009).
9. Hirschhaeuser F, Leidig T, Rodday B, Lindemann C, Mueller-Klieser W. Test system for trifunctional antibodies in 3D MCTS culture. J. Biomol. Screen 14, 980-990 (2009).
10. Gronau SS, Schmitt M, Thess B et al. Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract. Head Neck 27, 376-382 (2005). (Pubitemid 40593891)
11. Adema GJ, Hartgers F, Verstraten R et al. A dendritic-cell-derived C C chemokine that preferentially attracts naive T cells. Nature 387(6634), 713-717 (1997). (Pubitemid 27270612)
12. Robb RJ, Munck A, Smith KA. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J. Exp. Med. 154, 1455-1474 (1981). (Pubitemid 12235192)
13. Carter PJ. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6(5), 343-357 (2006).
14. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp. Cell. Res. 317(9), 1255-1260 (2011).
15. Baeuerle PA, Reinhardt C. Bispecific T cell engaging antibodies for cancer therapy. Cancer Res. 69(12), 4941-4944 (2009).
16. Gelderman KA, Lam S, Gorter A. Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs. Expert Opin. Biol. Ther. 5(12), 1593-1601 (2005). (Pubitemid 41771850)
17. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25(3), 158-164 (2004). (Pubitemid 38249490)
18. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443-446 (2000). (Pubitemid 30208162)
19. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov. Today 12, 898-910 (2007). (Pubitemid 350052671)
20. Kiewe P, Hasmuller S, Kahlert S et al. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin. Cancer Res. 12, 3085-3091 (2006). (Pubitemid 43837355)
21. Hirschhaeuser F, Walenta S, Mueller-Klieser W. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol. Immunother. 59, 1675-1684 (2010).
22. Racila E, Link BK, Weng WK et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin. Cancer Res. 14, 6697-6703 (2008).
23. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003). (Pubitemid 46606207)
24. Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2, 181-189 (2010)
25. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7, 2517-2527 (2008).
26. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115, 2914-2923 (2005). (Pubitemid 41434419)
27. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med. 195, 1653-1659 (2002). (Pubitemid 34666079)
28. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98, 2526-2534 (2001).
29. Haagen IA, Geerars AJ, Clark MR, van de Winkel JG. Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism. J. Immunol. 154, 1852-1860 (1995).
30. Koolwijk P, van de Winkel JG, Pfefferkorn LC et al. Induction of intracellular Ca2+ mobilization and cytotoxicity by hybrid mouse monoclonal antibodies. Fc gamma RII regulation of Fc-gamma RI-triggered functions or signaling? J. Immunol. 147, 595-602 (1991).
31. Lindhofer H, Hess J, Ruf P. Trifunctional Triomab® antibodies for cancer therapy. In: Bispecific Antibodies. Kontermann RE (Ed.). Springer-Verlag, Berlin, Heidelberg, Germany, 289-312 (2011).
32. Chelius D, Ruf P, Gruber P, Ploscher M et al. Structural and functional characterization of the trifunctional antibody catumaxomab. mAbs 2(3), 309-319 (2010).
33. Shen J, Zhu Z. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr. Opin. Mol. Ther. 10(3), 273-284 (2008). (Pubitemid 351799279)
34. Chames P, Baty D. Bispecific antibodies for cancer therapy. mAbs 1(6), 1-9 (2009).
35. Kim PS, Armstrong, TD, Song H et al. Antibody association with HER 2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J. Clin. Invest. 118, 1700-1711 (2008). (Pubitemid 351632374)
36. Müller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy. Biodrugs 24(2), 89-98 (2010).
37. Allen JE, Maizels RM. TH1 TH2: reliable paradigm or dangerous dogma? Immunol. Today 18(8), 387-392 (1997), (Pubitemid 27315712)
38. Alderson KL, Murphy WJ. Antigen specific memory T cells and their putative need for the generation of sustained anti-tumor responses. In: Memory T cells. Zanetti M, Schoenberger SP (Eds). Landes Bioscience and Springer Science + Business Media, NY, USA, 155-165 (2010).
39. Zanetti M, Castiglioni P, Ingulli E. Principles of memory CD8 T cells generation in relation to protective immunity. In: Memory T cells. Zanetti M, Schoenberger SP (Eds). Landes Bioscience and Springer Science + Business Media, NY, USA, 108-125 (2010).
40. Marzo AL, Yagita H, Lefrancois L. Migration to nonlymphoid tissue results in functional conversion of central to effector memory CD8 T cells. J. Immunol. 179, 36-40 (2007). (Pubitemid 46986514)
41. Heiss MM, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized Phase II/III trial. Int. J. Cancer 127, 2209-2221 (2010).
42. Burges A, Wimberger P, Kümper C et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a Phase I/II study. Clin. Cancer Res. 13(13), 3899-3905 (2007). (Pubitemid 47037597)
43. Heiss MM, Strohlein MA, Jäger M et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int. J. Cancer 117, 435-443 (2005). (Pubitemid 41429567)
44. Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (Removab®). J. Cancer 2, 309-316 (2011).
45. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. mAbs 2, 129-136 (2010).
46. Sebastian M, Kiewe P, Schuette W et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a Phase 1/2 study. J. Immunother. 32(2), 195-202 (2009).
47. Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J. Exp. Clin. Cancer Res. 28, 18 (2009).
48. Ströhlein MA, Lordick F, Rüttinger D et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: a open-label, multicenter, Phase I/II trial. Onkologie 34, 101-108 (2011).
49. Buhmann R, Simoes B, Stanglmaier M et al. Immunotherapy of recurrent B cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant. 43, 383-397 (2009).
50. Sebastian M, Passlick B, Friccius-Quecke H et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a Phase I study. Cancer Immunol. Immunother. 56, 1637-1644 (2007). (Pubitemid 47094393)
51. Stemmler HJ, Salat C, Lindhofer H et al. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. Anticancer Res. 25, 3047-3054 (2005). (Pubitemid 41044699)
52. Cardoso F, Dirix L, Conte P et al. Phase II study of single agent trifunctional antibody ertumaxomab (anti-HER-2 x anti-CD3) in HER 2 low expressing hormone-refractory advanced breast cancer patients (ABC). Presented at: 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010.
53. Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2 year review from a teaching hospital. Eur. J. Surg. Oncol. 22, 237-239 (1996). (Pubitemid 26229671)
54. Lindhofer H, Schoberth A, Pelster D et al. Elimination of cancer stem cells (CD133+/ EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: results from a pivotal Phase II/III study. J. Clin. Oncol. 27(Suppl. 15), 3014 (2009) (Abstract).
55. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004). (Pubitemid 39273735)
56. Perona R, López-Ayllón BD, de Castro Carpeño J, Belda-Iniesta C. A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. Clin. Transl. Oncol. 13, 289-293 (2011).
57. Wada J, Onishi H, Suzuki H et al. Surface-bound TGF-beta1 on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T cells in malignant effusions. Anticancer Res. 30(9), 3747-3757 (2010).
58. Jäger M, Schoberth A, Theissen B, Hess J, Friccius-Quecke H, Lindhofer H. Decrease of VEGF within malignant ascites during catumaxomab treatment: results from a pivotal Phase II/III study. J. Clin. Oncol. 27(Suppl. 15), 3029 (2009) (Abstract).
59. Jäger M, Schoberth A, Hennig M et al. The trifunctional antibody catumaxoma (anti-EpCAM x anti-CD3) in patients with malignant ascites: immunomonitoring results of a pivotal Phase II/III study (pooled population). J. Clin. Oncol. 28(Suppl. 15), 2521 (2010) (Abstract).
60. Jäger M, Schoberth A, Ruf P et al. Immunomonitoring results of Phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res. doi:10.1158/0008-5472. CAN-11-2235 (2011) (Epub ahead of print).
61. Hombach AA, Kofler D, Hombach A, Rappl G, Abken H. Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL 2. J. Immunol. 179, 7924-7931 (2007).
62. Heiss MM, Ströhlein MA, Bokemeyer C et al. The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: follow-up results from a Phase II/III study. J. Clin. Oncol. 29, 2512 (2011) (Abstract).
63. Sebastian M, Kiewe P, Schuette W et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x anti-CD3): results of a Phase 1/2 study. J. Immunother. 32, 195-202 (2009).
64. Taylor C, Hershman D, Shah N et al. Augmented HER 2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 13, 5133-5143 (2007). (Pubitemid 47502081)
65. Coiffier B, Thieblemont C, van Den Neste E et al. Long-term outcome of patients in the LNH 98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116, 2040-2045 (2010).
66. Reinhard H, Meyer SK, Bartels, K et al. The effect of trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer. J. Clin. Oncol. 29(Suppl.), 2601 (2011) (Abstract).
67. Ruf P, Jäger M, Förster B et al. Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites. J. Clin. Oncol. 29(Suppl.), 2575 (2011) (Abstract).
68. Ruf P, Kluge M, Jäger M et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br. J. Clin. Pharmacol. 69(6), 617-625 (2010).
69. Pietzner K, Jäger M, Schoberth A et al. First patient treated with re-challenge of catumaxomab in recurrent malignant ascites: a case report. Med. Oncol. doi:10.1007/ s12032-011-9961-9965 (2011) (Epub ahead of print).
70. Ott MG, Marmé F, Moldenhauer G et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal Phase II/III study in patients with malignant ascites. Int. J. Cancer doi:10.1002/ijc.26258 (2011) (Epub ahead of print).
71. Clark M. Antibody humanised: a case of the 'Emperor's new clothes'? Immunol. Today 21(8), 397-402 (2000). (Pubitemid 30612301)
72. Burton DR. Immunoglobulin G: functional sites. Mol. Immunol. 22, 161-206 (1985).
73. Schaefer W, Regula JT, Bähner M et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl Acad. Sci. USA 108, 11187-11192 (2011).
74. Asano R, Watanabe Y, Kawaguchi H et al. Highly effective recombinant format of humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J. Biol. Chem. 282, 27659-27665 (2007). (Pubitemid 47529493)
75. Kremmer E, Mysliwietz J, Thierfelder S. Induction and suppression of anti-antibodies to syngeneic T cell-binding antibodies in mice. Clin. Exp. Immunol. 109, 180-184 (1997). (Pubitemid 27293901)
76. Benjamin RJ, Cobbold SP, Clark MR, Waldmann H. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J. Exp. Med. 163, 1539-1552 (1986). (Pubitemid 16043471)
77. Van Assche G, Séverine Vermeire S, Rutgeerts P. Management of loss of response to anti-TNF drugs: change the dose or change the drug? J. Crohns Colitis 2, 348-351 (2008).
78. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp. Hematol. 36, 997-1003 (2008).